September 1963, 31% were alive and possibly cured when assessed 2 years later. This included over 50 % of brain tumours, 84% of retinoblastomas, and 54% of connective tissue tumours. Of our own cases in Liverpool the 2-year survival time for Wilms' tumours is now about 50%. Although the commonest form of malignant disease in childhood, that is acute leukaemia, remains obstinately fatal, even here considerable progress has been made.
Leukaemia
In nearly all children with acute lymphoblastic leukaemia, complete remissions lasting a year or more can now be obtained, and during this time the child is in good health and is able to enjoy a normal life. A small but significant number of very long survivors is now known, and Burchenal has collected details of 75 children with acute leukaemia who have survived in complete remission for at least five years. Some have subsequently relapsed even after this period, but practically none of those who have survived eight years or more have relapsed and they may possibly be cured. So far there is no common factor among these long survivals which has given a real clue to the fortunate outcome. They have been treated in many different ways; some have had long periods of maintenance therapy with drugs while others have not received any maintenance therapy or have only received it for a relatively short time. The total population of leukaemic children from whom these long survivors were drawn is not accurately known, but a reasonable estimate would be that approximately 1 in 1000 cases may be expected to have such prolonged remission and possibly to be cured. I have been fortunate enough to treat two such patients, one of whom has been in complete remission for 10 years, and the other for 8 years. A third patient has been in remission for nearly 5 years with two slight interruptions due to local recurrences in each testis. These were successfully treated with radiotherapy and the haematological remission continued undisturbed. It has been observed in eight other cases of long survival that local recurrences in the gonads have occurred and have been successfully treated.
With all forms of malignant disease in childhood being so uncommon, the occurrence of two or more cases within a relatively short distance of each other both in space and time has aroused interest because of its possible aetiological significance. One such cluster which was studied in some detail occurred in the Chicago suburb of Niles where, between September 1957 and August 1960, 8 children developed acute leukaemia, a highly significant increase over the expected incidence for this community. All 8 children lived in a neighbourhood served by one Roman Catholic parish. Of the 8, 7 were from Catholic families and at the time of onset these 7 children either attended, or had older sibs attending, the only Catholic elementary school in the neighbourhood. The leukaemia occurred within two distinct periods and, during the same times, there was an outbreak of a rheumaticlike illness in other children attending the same school. Also during the same period there was a significant increase of deaths associated with congenital heart disease. A similar association between an increased incidence of leukaemia and of deaths from congenital heart disease in the same community was noted in the small town of Orange in Texas in 1960. Between March and December 1960 3 children died from acute leukaemia, whereas no other cases of leukaemia in children were diagnosed in Orange during the previous five years. In the succeeding year, 5 full-term babies died within two weeks of birth, with severe cardiac malformations, 2 of them being accompanied by tracheo-oesophageal fistulae. Regional studies of the incidence of childhood leukaemia have shown that the incidence of pairs of cases occurring within a defined period of time and space is higher than would be expected by random occurrence. In a recent study in Liverpool Dr. Dorothy Mainwaring used the technique developed by Knox for the investigation of low intensity epidemics and found that 11 pairs of patients living less than 1 km. apart developed symptoms within less than a year of each other.
The occurrence of clusters, pairing, increased incidence of congenital malformations, and outbreaks of an obscure illness, as in the Niles epidemic, all provide food for speculation, especially speculation as to the viral aetiology and possible infectivity of the disease. It is difficult to accept any theory that acute leukaemia is a virus infection which can affect any child. The incidence is so low that there must be some other factors operating that would render a child unduly susceptible to such infection. Among these factors could be genetic susceptibility and impairment of host resistance by intrauterine Infection of neonatal mice with reo virus III has produced lymphomata that were very similar to the Burkitt tumour. Stanley has also shown that mice infected with reo type III may develop an acute illness with steatorrhoea, jaundice, tremors, and emaciation, and, if they survive this, may go on to a chronic immunological disease, with runting, marked splenic atrophy, and leucopenia. Spleen cells from these mice given to isogenic newborn mice produce an acute and fatal runting syndrome in half the subjects. The mice that survive this may also develop lymphomata. The interesting link here is between the production of malignant disease on the one hand, or auto-immune disease on the other, by the same virus.
Another fascinating feature of the Burkitt tumour is the dramatic response to short intensive courses of chemotherapy that has been achieved in some cases. The effective drugs have been cyclophosphamide and methotrexate, but improvement has also been obtained with vincristine, melphalan, and orthomelphalan. Some patients have remained in remission, with total tumour regression, for six years. About 20% of treated patients are surviving without evidence of disease, and this is the most remarkable achievement of chemotherapy in any form of cancer. As transfusion of plasma from successfully treated patients has produced regression of tumour in other patients and as spontaneous regression of tumour has also been seen, there is some evidence of an immune response to the tumour. It has also been shown that serum from successfully treated patients, when tested by a fluorescent antibody technique against various types of cell from Burkitt tumours, reacts more positively than that from patients who have shown only partial or no remission. Attempts have been made to increase the reactivity of the host by vaccinia and BCG vaccination and by irradiated tumour cell vaccines.
Leukaemic changes seldom occur in Burkitt tumour patients but they have been seen in patients with similar tumours in the United States. Dissemination of the tumour cells in the blood to produce a leukaemic state may well be controlled by factors in the host, and those patients who are antigenically 'highly-titred' by repeated exposure to infection may thus be able to localize the tumour more effectively. In acute leukaemia of temperate zones it has long been recognized that patients whose initial white count is normal or low survive longer than those with high counts, and Zuelzer has suggested that the differences might be immunological, the low count patients retaining some control while the high count 75 cases of tumours of the sympathetic nervous system, the majority of which were presumably neuroblastoma. These tumours are occasionally truly congenital in the sense that they are present at birth, and one of our own cases was detected on routine abdominal examination on the second day of life. The majority of cases originate in the abdomen but may metastasize quite early, and the presenting symptoms may be the result of metastatic spread elsewhere. An important characteristic of these tumours is that they usually secrete large quantities of catecholamines and their metabolites. This is not only of diagnostic significance but also of value in prognosis, because incomplete removal of the primary tumour, the presence of residual metastases, or recurrent disease produces an increase in the urinary catecholamine excretion. This may be found before there is unequivocal clinical or radiological evidence of such recurrence. In addition to the total catecholamines, the metabolites studied are normetadrenaline and metadrenaline and 4-hydroxy-3-methoxy mandelic acid (VMA). On the basis of the pattern of excretion three groups of cases were recognized. Group I has. an increase in all components. In Group II the total catecholamine excretion is much increased but VMA is only slightly increased or normal. The prognosis in this group in one series appeared to be much worse than in the others. In the third group the total catecholamines are only slightly increased, if at all, but there is an increase in VMA and normetadrenaline. This group appeared to have a better prognosis in the small series of cases reported. Our policy in the treatment of neuroblastoma has been complete removal of the primary tumour if possible. After operation the patient is kept under review and repeated urinary examinations for catecholamine excretion are performed at lengthening intervals. If there is no clinical or chemical sign of recurrence at the end of a two-year period, it is hoped that the patient is cured and we have not seen any recurrences after this length of time. If the tumour is inoperable or cannot be completely removed, partial operation is done followed by local radiotherapy. Skeletal metastases, which are usually widespread, have been treated with chemotherapy. Actinomycin D has not been very effective in our hands though others have reported some transient benefit from its use. We have found that vincristine has a dramatic though temporary effect in some cases in producing rapid relief of pain, fall in temperature, and improvement in well-being. Partial or complete resolution of skeletal metastases has occasionally occurred, but the improvement has only been of temporary duration. Cyclophosphamide has also been of some value in producing symptomatic and radiological improvement. Very occasionally these tumours may regress spontaneously, the tumour changing its nature from a malignant invasive one to a benign non-invasive one which histologically may be diagnosed as a ganglioneuroma. The chances of this occurring appear to be extremely small but, in view of the possibility, vigorous attempts at therapy are always justified. It was on the basis of this apparent maturation from an immature to a mature cell that Bodian first suggested and subsequently tried the use of massive doses of vitamin B12 on the mistaken analogy with the maturation of immature cells in megaloblastic anaemias. He reported some remarkable results though the comment must be made that the majority of these were in infants, in whom the prognosis is undoubtedly better than in older children. Furthermore, no case with bony metastases has shown permanent clinical remission of the disease. Many of the patients have been treated with radiotherapy and operation in addition to the vitamin B12, though surgery in some of these patients consisted of biopsy only. Practically no other observer has managed to obtain any significant improvement with the use of vitamin B12, but at least it has the merit of being harmless, which is more than can be said for most Other tumours. Our experience with chemotherapy in other types of childhood tumour has been very limited. One girl who had extensive subcutaneous metastases from a synovial sarcoma showed considerable regression of tumours following treatment with actinomycin D, but the improvement was temporary and she died six months later. A boy with pulmonary metastases from a hepatoblastoma showed distinct improvement in the radiological appearances after treatment with TEM (triethylenemelamine) but again the improvement was temporary. The fact that recognizable improvement of any degree occurred is, however, of some significance and offers hope for further developments in this field.
One of the major disadvantages of chemotherapy for cancer is that the drugs used are necessarily very toxic to normal tissues and this severely limits the dose that can be used. To try and overcome this, techniques have been developed for localized or regional perfusion of the tumour with partial or total exclusion of the remainder of the body. We have used these techniques in a few patients though the technical difficulties in small children are somewhat daunting. In one patient who had a rhabdomyosarcoma in the region of the anus, there were several recurrences after excision and after radiotherapy. The tumour began to grow rapidly, fungated through the skin, and caused great discomfort and pain. As there was very little response to conventional chemotherapy with cyclophosphamide both orally and intravenously, it was decided to try direct arterial perfusion into the tumour area. A polythene catheter was inserted through the femoral artery to the level of the bifurcation of the aorta, and cyclophosphamide was injected every 2 hours in a dosage of 12-5 mg. In the following week there was considerable regression in the size of the tumour but unfortunately she developed generalized septicaemia and gangrene of the distal part of the leg. Another child with rhabdomyosarcoma of the orbit was treated with intra-arterial infusion with methotrexate through cannulae inserted into the internal and external carotid arteries. 25 mg. methotrexate was given daily by slow intra-arterial drip, and each day 5 mg. citrovorum factor (folinic acid) were given intramuscularly twice daily to prevent the systemic toxic effects of the drug. The intra-arterial perfusion was maintained for nearly 5 weeks, and during this period 21 injections of methotrexate were given. There were many complications, including infection of the wound in the neck and severe stomatitis of the left side of the mouth, that is the side on which the infusion was given. Despite this, the child tolerated the treatment extremely well and there was considerable shrinkage of the tumour and relief of pain. However, even during the course of the treatment, the tumour began to enlarge and the procedure was abandoned. She died 3 months later. Two children have had localized perfusion of malignant tumours of the pelvis. In this technique the circulation of the perfused area is isolated from the general circulation. The first patient was a child who had a congenital sacrococcygeal tumour excised when she was a few days old. Three years later a local recurrence occurred in the left buttock and biopsy revealed an anaplastic adenocarcinoma. The tumour was growing rapidly and soon filled the whole of the true pelvis, compressing the rectum and producing obstruction of the bladder neck. There was no possibility of excising it, and so it was decided to try the effect of intraarterial perfusion. The aorta, inferior vena cava, and right common iliac arteries were isolated and clamped, and, through an incision in the left groin, the femoral artery and vein were cannulated and perfused with warmed, oxygenated, heparinized blood. The pressure in the isolated circulation was adjusted so that it was much lower than the systemic circulation in order that any leak in the system would be from the general circulation to the perfused area and not vice versa. Mustine hydrochloride in a dose of 5 mg. was then injected intraarterially, followed by a second dose of 2-5 mg., half an hour later. The isolated circulation was maintained for a further hour to allow the drug to be fixed by the tissues. Normal circulation was then resumed and a colostomy performed. Over the next 10 days considerable shrinkage of the tumour occurred, she then developed signs of intestinal obstruction and laparotomy was performed. At exploration the tumour was found to have shrunk right down to the floor of the pelvis. Two weeks later, as the external part of the tumour was growing rapidly once more, further operation was performed in which the mass on the buttock was excised and the shrunken remains of the pelvic tumour, together with the rectum, were removed. After operation she was maintained on treatment with 50 mg. cyclophosphamide daily and she was discharged home. She remained remarkably well for a few months, but about six months after the perfusion she had evidence of massive hepatic metastases and she died a few weeks later. A second patient who had had partial excision of the contents of the pelvis for rhabdomyosarcoma, was 558 Saul Keidan group.bmj.com on June 23, 2017 -Published by http://adc.bmj.com/ Downloaded from also treated with localized perfusion, this time using actinomycin D. Unfortunately, there were many technical difficulties during the operation, culminating in a massive leak into the systemic circulation and she did not survive the procedure. Technically it would obviously be much simpler to perform isolated perfusion in the limbs than in abdominal pelvic tumours, but the opportunity to use this technique has not yet arisen.
I have deliberately omitted discussing the management of cerebral tumours and bone tumours as I had very little personal experience in dealing with these. I have also omitted any detailed discussion of the management of histiocytosis in childhood as, though this group of disorders is frequently classed as neoplastic, the evidence for this is by no means convincing. The precise type of pathological process involved remains uncertain. In some ways the most severe systemic form of histiocytosis, Letterer-Siwe's disease, tends to behave like a neoplasm in its remorseless progression and fatal termination and, like other neoplastic disorders, it is amenable to treatment with cytotoxic drugs so that prolonged remissions or even possible cure can be obtained. One of our patients who was extremely ill as an infant with systemic histiocytosis is now, at the age of 8 years, in fairly good health and is no longer on any form of therapy. Vinblastine, cyclophosphamide, and corticosteroid drugs seem to be the most useful agents at the present time. The local application of folic acid antagonists, particularly methotrexate, to the skin lesions caused considerable improvement in one of our patients and is certainly worth a trial.
Comment
Although the largest experience that I have had is in the management of acute leukaemia in childhood, this really needs a lecture on its own.
It will be clear that the management of malignant disease in childhood leaves very much to be desired, but treatment does have something to offer, and chemotherapy in particular is still only in its infancy. The very fact that some drugs can produce regression in some tumours is of the greatest importance and encourages one to believe that further progress along these lines is highly probable. So far practically every drug that has proved to be of any value has been discovered empirically, often in the search for something entirely different. The vinca alkaloids, vincristine and vinblastine for instance, were discovered because of a belief that extracts from the Madagascar periwinkle had an antidiabetic effect. Laboratory investigation failed to confirm that there was any hypoglycaemic effect but in one laboratory it was observed that certain fractions of the plant produced bone-marrow depression in rats. Continued investigation led to the isolation of vinblastine which was then shown to have an oncolytic effect against transplanted mouse leukaemia. Actinomycin D was discovered in the systematic search for new antibiotics from soil organisms. This particular extract was found to have antibacterial effects but was far too toxic for use in man. It was 12 years after its initial isolation that it was first found to have a carcinolytic effect, and 14 years before the first published reports of its trials in man. The deliberate design of chemotherapeutic agents must depend on increasing knowledge of biochemical differences between normal and malignant cells and on differences in various forms of malignant disease. Thus cyclophosphamide was synthesized as a combination of nitrogen mustard and a phosphoric acid ester in the hope that it would be activated by splitting off the active portion of the molecule only in tumour tissues rich in phosphatases and phosphamidases. In fact the drug appears to be split mainly in the liver but nevertheless has proved to be a very useful drug.
The actual technique of using drugs also requires much more study. The place of oral, intravenous, intra-arterial infusion, perfusion in an isolated circulation, and endolymphatic administration are all of value in different situations, but experience in their use, particularly in children, remains limited because of the infrequency with which sufficient cases are seen at any one centre.
Burchenal has recently raised a number of pertinent questions in discussing cancer research with particular reference to chemotherapy. Among these questions are the following.
1. Why is it that some tumours are initially very sensitive to chemotherapeutic agents, whereas others are initially refractory ? 2. What is the relative differential sensitivity to a new agent of normal versus cancer tissues ? Thus a drug might be found which had a very strong tissue specificity, both normal and malignant, but did not affect other organs and tissues. For instance, a drug might completely destroy normal breast tissue as well as breast carcinoma at a level of dosage which caused no damage at all on any other vital tissue. Conversely, another drug might destroy breast carcinoma without damaging normal breast tissue, but only at a dosage where it would also damage bone-marrow or gastro-intestinal epithelium, and it would, therefore, be useless from a practical point of view.
3. What is the relation of the site of the tumour or metastases to sensitivity ? Sometimes, for instance, the metastases may be more sensitive to a drug than the primary tumour. 4. How close is the relation between the inhibition of metabolic pathways and the toxic or therapeutic effects ? If more were known about this it might be possible to prevent toxicity while maintaining the therapeutic effect.
5. How important are the schedule and technique of doses with a given drug ? Is there a periodicity in the sensitivity of normal tissues so that deliberately timed dosage of the drug might minimize toxic effects ?
6. What part, if any, do the host defences of the patient play?
Among further questions that might be raised are those concerning the techniques of development of chemotherapeutic drugs. At present these are largely based on the effect of agents, either extracted or synthesized, on experimental transplanted animal tumours. The number of compounds so tested runs into many thousands and yet relatively little of clinical value has developed. Two types of compound that have been of real value in clinical chemotherapy, on the other hand, were first used in man before either was shown to have any antitumour activity in animals. The nitrogen mustards, for instance, were first synthesized as potential war gases. Because of their leucopenic effect, which had been noted in men who had been accidentally exposed to them, they were then tried, in conditions of the greatest secrecy, in a number of patients with advanced malignant disease, particularly Hodgkin's disease, where they were found to have an inhibitory effect on the tumour. Folic acid antagonists were first tried in children with acute leukaemia following the observation that folic acid analogues appeared to hasten the progress of the disease. It was only after the original work on man that animal experimental systems were used. Although it is obviously undesirable that newly synthesized compounds should be used on human patients in the first instance, it is also clear that the methods of animal trials are far from ideal. Many compounds that have had remarkable effects in inhibiting the growth of animal tumours have proved quite ineffective in human tumours or else have been far too toxic. Other methods of testing drugs are indeed widely used now. These include tissue cultures of human tumours and the growth of human tumours in pretreated animal hosts. How far do these systems bear any resemblance to the tumour growing in the natural host ? Would it be possible to devise other systems that would more closely represent the natural history of tumours ? The part played by immunological mechanisms in the control or lack of control of malignant disease has had little study hitherto but may be of the greatest importance. Studies in this University by Professor Nairn and his colleagues have shown that there are immunological differences between normal and malignant cells and these differences might be possible to exploit, as suggested by Nairn, by coupling tumour specific antibody with a cytotoxic agent. Professor Woodruff has said that not very long ago even to have suggested that immunology would contribute to our understanding of the behaviour of tumours and the development of new methods of treating them, would have seemed quite absurd. Today it seems a reasonable line of approach and he wonders how it will appear in another 60 years time.
